More than 90% of breast cancer patients are diagnosed with early-stage disease, and around 70% of them have tumors that are estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) [1, 2]. This evidence concerns the gene ERBB2 and breast carcinoma.